1. Pischon T., Lahmann P.H., Boeing H. et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006; 118: 728 - 38.

2. Petejova N., Martinek A. Renal cell carcinoma: Review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160(2), 183 - 94. DOI: 10.5507/bp.2015.050.

3. Sasco A.J., Secretan M.B., Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004; 45 (Suppl 2): 3 - 9. DOI: 10.1016/j.lungcan.2004.07.998.

4. Chittiboina P., Lonser R.R. von Hippel-Lindau disease. Hand Clin Neurol 2015; 139 - 56. DOI: 10.1016/b978-0-444-62702-5.00010-x.

5. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394 - 424. DOI: 10.3322/caac.21492.

6. Злокачественные новообразованияв России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России, 2018. 250 с.

7. Международная классификация болезней 10-го пересмотра. Версия 2019. Доступно по: https://mkb-10.com/.

8. Moch H., Cubilla A.L., Humphrey P.A. et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol 2016; 70(1): 93 - 105.

9. Moch H., Humphrey P.A., Ulbright T.M., Reuter V.E. WHO (World Health Organization). Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours. IARC Press, Lyon, France, 2016.

10. Brierley J.D., Gospodarowicz M.K., Wittekind C. Eds. TNM Classification of Malignant Tumours. 8th edn. Oxford, UK: Wiley-Blackwell, 2017.

11. Kutikov A., Uzzo R.G. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009; 182(3): 844 - 53.

12. Ficarra V., Novara G., Secco S. et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol 2009; 56: 786 - 93.

13. Novick A.C., Cosgrove D.M. Surgical approach for removal of renal cell carcinoma extending into the vena cava and the right atrium. J Urol 1980; 123: 947 - 50.

14. Motzer R.J., Mazumdar M., Bacik J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17(8): 2530 - 40.

15. Heng D.Y.., Xie W., Regan M.M. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 2009; 27(34): 5794 - 9.

16. Israel G.M., Bosniak M.A. How I do it: evaluating renal masses. Radiology 2005; 236(2): 441 - 50.

17. Patard J.J., Leray E., Rodriguez A. et al. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol 2003; 44(2): 226.

18. Lee C.T., Katz J., Fearn P.A., Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol 2002; 7(4): 135 - 40.

19. Sacco E., Pinto F., Sasso F. et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int 2009; 83(1): 1 - 11.

20. Kim H.L., Belldegrun A.S., Freitas D.G. et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003; 170(5): 1742 - 6.

21. Magera J.S.Jr., Leibovich B.C., Lohse C.M. et al. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology 2008. 71(2): 278.

22. Chen Z., Shao Y., Yao H. et al. Preoperative albumin to globulin ratio predicts survival in clear cell renal cell carcinoma patients. Oncotarget. 2017; 8(29): 48291 - 48302.

23. Abel E.J., Thompson R.H., Maqulis V. et al. Perioperative outcomes following surgical resection of renal cell carcinoma with inferior vena cava thrombus extending above the hepatic veins: a contemporary multicenter experience. Eur Urol 2014; 66(3): 584 - 92.

24. Волкова М.И. "Стратегия хирургического лечения больных локализованным и местно-распространенным раком почки". Дисс...докт. мед. наук. - М. - 2015.

25. Shen J., Chen Z., Fan M. et al. Prognostic value of pretreatment neutrophil count in metastatic renal cell carcinoma: a systematic review and meta-analysis. Cancer Manag Res 2019; 11: 5365 - 74. DOI: 10.2147/cmar.s199849.

26. A., Lubas A., Stec R. et al. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and c-reactive protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: a systemic review and meta-analysis. Clin Genitourinary Cancer 2018; 16(3): e685 - e693. DOI: 10.1016/j.clgc.2018.01.010

27. Hu X., Wang Y., Yang W.X. et al. Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis. Cancer Manag Res 2019; 11: 6163 - 73. DOI: 10.2147/CMAR.S208839. eCollection 2019.

28. Buntinx F., Wauters, H. The diagnostic value of macroscopic haematuria in diagnosing urological cancers: a meta-analysis. Family Practice 1997; 14(1): 63 - 8. DOI: 10.1093/fampra/14.1.63.

29. Kara ., Maurice M.J., Mouracade P. et al. Preoperative proteinuria is associated with increased rates of acute kidney injury after partial nephrectomy. Int Braz J Urol 2019; 45. DOI: 10.1590/S1677-5538.IBJU.2018.0776.

30. Potretzke A.M., Knight B.A., Vetter J.M. et al Diagnostic utility of selective upper tract urinary cytology: a systematic review and meta-analysis of the literature. Urology 2016; 96: 35 - 43. DOI: 10.1016/j.urology.2016.04.030.

31. Rossi S.H., Hsu R., Blick C. et al. Meta-analysis of the prevalence of renal cancer detected by abdominal ultrasonography. Br J Surg 2017; 104(6): 648 - 59. DOI: 10.1002/bjs.10523.

32. Vogel C., B., Ljungberg B. et al. Imaging in Suspected Renal Cell Carcinoma: Systematic Review. Clin Genitourin Cancer 2019; 17(2): 345 - 55. DOI: 10.1016/j.clgc.2018.07.024.

33. Salameh J.P., McInnes M.D.F., McGrath T.A. et al. Diagnostic accuracy of dual-energy ct for evaluation of renal masses: systematic review and meta-analysis. AJR Am J Roentgenol 2019; 212(4): W100-5. DOI: 10.2214/AJR.18.20527.

34. Sevcenco S., Spick C., Helbich T.H. et al. Malignancy rates and diagnostic performance of the Bosniak classification for the diagnosis of cystic renal lesions in computed tomography - a systematic review and meta-analysis. Eur Radiol 2016; 27(6): 2239 - 47. DOI: 10.1007/s00330-016-4631-9.

35. Kang S.K., Chandarana H. Contemporary imaging of the renal mass. Urol Clin North Am 2012; 39: 161 - 70.

36. Israel G.M., Bosniak M.A. An update of the Bosniak renal cyst classification system. Urology 2005; 66: 484 - 8.

37. Chiarello M.A., Mali R.D., Kang S.K. Diagnostic accuracy of MRI for detection of papillary renal cell carcinoma: a systematic review and meta-analysis. AJR Am J Roentgenol 2018; 211(4): 812 - 21. DOI: 10.2214/AJR.17.19462.

38. Nomoto N., Tani T., Konda T. et al. Primary and metastatic cardiac tumors: echocardiographic diagnosis, treatment and prognosis in a 15-years single center study. J Cardiothorac Surg. 2017; 12(1): 103.

39. Calderone C.E., Tuck B.C., Gray S.H. et al. The role of transesophageal echocardiography in the management of renal cell carcinoma with venous tumor thrombus. Echocardiography 2018; 35(12): 2047 - 55. DOI: 10.1111/echo.14187.

40. Zlatanovic P., Koncar I., Jakovljevic N. et al. transesophageal echocardiography-guided thrombectomy of level IV renal cell carcinoma without cardiopulmonary bypass. Braz J Cardiovasc Surg 2019; 34(2): 229 - 32. DOI: 10.21470/1678-9741-2018-0216.

41. Kostibas M.P., Arora V., Gorin M.A. et al. Defining the role of intraoperative transesophageal echocardiography during radical nephrectomy with inferior vena cava tumor thrombectomy for renal cell carcinoma. Urology 2017; 107: 161 - 5. DOI: 10.1016/j.urology.2017.03.008.

42. Larcher A., Dell"Oglio P., Fossati N. et al. When to perform preoperative chest computed tomography for renal cancer staging. BJU Int 2017; 120(4): 490 - 6. DOI: 10.1111/bju.13670. Epub 2016 Nov 2.

43. Miles K.A., London N.J., Lavelle J.M. et al. CT staging of renal carcinoma: a prospective comparison of three dynamic computed tomography techniques. Eur J Radiol 1991; 13(1): 37 - 42.

44. Heidenreich A., Ravery V. Preoperative imaging in renal cell cancer. World J Urol 2004; 22(5): 307 - 15.

45. Sheth S., Scatarige J.C., Horton K.M. et al. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT. Radiographics 2001. S237.

46. Lim D.J., Carter M.F. et al. Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoa. J Urol 1993; 150(4): 1112.

47. Taylor A.Jr., Nally J.V. Clinical applications of renal scintigraphy. AJR Am J Roentgenol. 1995; 164: 31 - 41.

48. Uzzo R.G., Novick A.C. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001; 166(1): 6 - 18.

49. Huang W.C., Levey A.S., Serio A.M. et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7(9): 735 - 40.

50. Sohaib S.A., Cook G., Allen S.D. et al. Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer. Br J Radiol. 2009; 82(980): 632 - 639.

51. Larcher A., Muttin F., Fossati N. et al. When to perform preoperative bone scintigraphy for kidney cancer staging: indications for preoperative bone scintigraphy. Urology 2017; 110: 114 - 20. DOI: 10.1016/j.urology.2017.08.043.

52. Henriksson C., Haraldsson G., Aldenborg F. et al. Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma. Scand J Urol Nephrol 1992; 26(4): 363 - 6.

53. Seaman E., Goluboff E.T., Ross S, Sawczuk I.S. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology 1996; 48(5): 692 - 5.

54. A., Witkowska-Patena E., Stembrowicz-Nowakowska Z. et al. Long bone metastases as predictors of survival in patients with metastatic renal cancer Nucl Med Rev Cent East Eur 2015; 18(2): 89 - 91. DOI: 10.5603/NMR.2015.0021.

55. Prins F.M., van der Velden J.M., Gerlich A.S. et al. Superior target delineation for stereotactic body radiotherapy of bone metastases from renal cell carcinoma on MRI compared to CT. Ann Palliat Med 2017; 6(Suppl. 2): S147 - S154. DOI: 10.21037/apm.2017.06.07.

56. Nomoto Y., Tsukie T., Kurita A. et al. Metastatic renal cell carcinoma initially presented with a longitudinally extensive spinal cord lesion on MRI. Rinsho Shinkeigaku 2016; 56(5): 348 - 51. DOI: 10.5692/clinicalneurol.cn-000850.

57. Bhattacharjee P.K., Ahmed T.U., Hoque R. et al. Comparison Between Whole body Bone Scintigraphy and Regional CT Scan in the Diagnosis to Bone Metastasis of Cancer Patients. Nuclear Science and Applications. 2015; 24(1): 33

58. V., Eberhardt B., Bex A. et al. An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol. 2018; 15: 511 - 521 DOI: 10.1038/s41585-018-0034-9.

59. Yang H.L., Liu T., Wang X.M. et al. Diagnosis of bone metastases: a meta-analysis comparing <18> FDG PET, CT, MRI and bone scintigraphy. Eur Radiol. 2011; 21(12): 2604 - 17. DOI: 10.1007/s00330-011-2221-4.

60. Fink K.R., Fink J.R. Imaging of brain metastases. Surg Neurol Int. 2013; 4 (Suppl. 4): S209 - 19.

61. Marshall M.E., Pearson T., Simpson W. et al. Low incidence of asymptomatic brain metastases in patients with renal cell carcinoma. Urology 1990; 36(4): 300 - 2.

62. Ha F.J., Spain L., Dowling A. et al. Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study. Asia Pac J Clin Oncol 2019. DOI: 10.1111/ajco.13109.

63. Tomiyama A., Nakayama H., Aoki K., Ueda M. Solitary metastasis of renal cell carcinoma to the third ventricular choroid plexus with rapid clinical manifestation by intratumoral hemorrhage. Neurol India 2008; 56(2): 179 - 81.

64. El Ali Z., Rottey S., Barthelemy P. et al. Brain metastasis and renal cell carcinoma: prognostic scores assessment in the era of targeted therapies. Anticancer Res 2019; 39(6): 2993 - 3002. DOI: 10.21873/anticanres.13431.

65. Takeshita N., Otsuka M., Kamasako T. et al. Prognostic factors and survival in Japanese patients with brain metastasis from renal cell cancer. Int J Clin Oncol 2019. DOI: 10.1007/s10147-019-01474-2.

66. Lamb G.W., Bromwich E.J., Vasey P., Aitchison M. Management of renal masses in patients medically unsuitable for nephrectomy - natural history, complications, and outcome. Urology 2004; 64(5): 909 - 13.

67. Hallscheidt P., Besharati S., Noeldge G. et al. Preoperative and palliative embolization of renal cell carcinomas: follow-up of 49 patients. Rofo 2006; 178(4): 391 - 9.

68. Schwartz M.J., Smith E.B., Trost D.W., Vaughan E.D.Jr. Renal artery embolization: clinical indications and experience from over 100 cases. BJU Int 2007; 99(4): 881 - 6.

69. Maxwell N.J., Saleem A.N, Rogers E. et al. Renal artery embolisation in the palliative treatment of renal carcinoma. Br J Radiol 2007; 80(950): 96 - 102.

70. R.O. Evaluation of vascular bed before and after embolization of renal artery for renal cancer. Klin Khir 2015; 1: 32 - 4.

71. Ma H., Shen G., Liu B. et al. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun 2017; 38(2): 156 - 63. DOI: 10.1097/MNM.0000000000000618.

72. Lindenberg L., Mena E., Choyke P.L., Bouchelouche K. PET imaging in renal cancer. Curr Opin Oncol 2019; 31(3): 216 - 21. DOI: 10.1097/CCO.0000000000000518.

73. Wang H.Y., Ding H.J., Chen J.H. et al. Meta-analysis of the diagnostic performance of [18F] FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging 2012; 12: 464 - 74. DOI: 10.1102/1470-7330.2012.0042.

74. Gofrit O.N., Orevi M. Diagnostic challenges of kidney cancer: a systematic review of the role of positron emission tomography-computerized tomography. J Urol 2016; 196(3): 648 - 57. DOI: 10.1016/j.juro.2016.02.2992.

75. Caldarella C., Muoio B., M.A. et al. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. Radiol Oncol 2014; 48(3): 219 - 27. DOI: 10.2478/raon-2013-0067.

76. Marconi L., Dabestani S., Lam T.B. et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016; 69(4): 660 - 73. DOI: 10.1016/j.eururo.2015.07.072.

77. Richard P.O., Jewett M.A., Bhatt J.R. et al. Renal tumor biopsy for small renal masses: a single-center 13-year experience. Eur Urol 2015; 68(6): 1007 - 13.

78. Volpe A., Mattar K., Finelli A. et al. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol 2008; 180: 2333.

79. Shannon B.A., Cohen R.J., de Bruto H., Davies R.J. The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J Urol 2008; 180(4): 1257 - 61.

80. Veltri A., Garetto I., Tosetti I. et al. Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases. Eur Radiol. 2011; 21(2): 393.

81. Maturen K.E. et al. Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol. 2007; 188(2): 563 - 70.

82. Alle N., Tan N., Huss J. et al. Percutaneous image-guided core biopsy of solid renal masses: analysis of safety, efficacy, pathologic interpretation, and clinical significance. Abdom Radiol (NY). 2018; 43(7): 1813 - 1819.

83. Eshed I., Elias S., Sidi A.A. Diagnostic value of CT-guided biopsy of indeterminate renal masses. Clin Radiol. 2004; 59(3): 262 - 7.

84. B.K., Arda K., Aktas E. et al. Percutaneous US-guided needle biopsies of solid renal masses. Neoplasma. 2011: 58(2): 146 - 52.

85. Leveridge M.J., Finelli A., Kachura J.R. et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol 2011; 60(3): 578 - 84. DOI: 10.1016/j.eururo.2011.06.021.

86. Deng J., Li L., Xia H., Guo J. et al. A comparison of the prognosis of papillary and clear cell renal cell carcinoma: Evidence from a meta-analysis. Medicine (Baltimore) 2019; 98(27): e16309. DOI: 10.1097/MD.0000000000016309.

87. S., Hofmann F., Tahbaz R. et al. A Systematic Review and Meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol 2017; 71(3): 426 - 36. DOI: 10.1016/j.eururo.2016.11.020.

88. Ng K.L., Morais C., Bernard A. et al. A systematic review and meta-analysis of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma. J Clin Pathol 2016; 69(8): 661 - 71. DOI: 10.1136/jclinpath-2015-203585.

89. Gu L., Li H., Wang Z. et al. A systematic review and meta-analysis of clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with tumor thrombus treated by radical nephrectomy with thrombectomy. Cancer Treat Rev 2018; 69: 112 - 20. DOI: 10.1016/j.ctrv.2018.06.014.

90. Zhang Z., Yu C., Velet L. et al. The Difference in prognosis between renal sinus fat and perinephric fat invasion for pt3a renal cell carcinoma: a meta-analysis. PLoS One 2016; 11(2): e0149420. DOI: 10.1371/journal.pone.0149420.

91. Chen L., Li H., Gu L. et al. Prognostic role of urinary collecting system invasion in renal cell carcinoma: a systematic review and meta-analysis. Sci Rep 2016; 6: 21325. DOI: 10.1038/srep21325.

92. Zhang L., Wu B., Zha Z. et al. The correlation of clinicopathological features with the status of surgical margins in renal cell cancer patients following nephron-sparing surgery: a systematic review and meta-analysis. Front Oncol 2019; 9: 648. DOI: 10.3389/fonc.2019.00648.

93. Carlo M.I., Hakimi A.A., Stewart G.D. et al. Familial kidney cancer: implications of new syndromes and molecular insights. Eur Urol 2019; pii: S0302-2838(19)30500-7. DOI: 10.1016/j.eururo.2019.06.015.

94. Hampel H., Bennett R.L., Buchanan A. et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med 2015; 17(1): 70 - 87. Doi: 10.1038/gim.2014.147.

95. Nordstrom-O'Brien M., van der Luijt R.B., van Rooijen E. et al: Genetic analysis of von Hippel-Lindau disease. Hum Mutat 2010; 31: 521 - 37.

96. C., Joly D., Gallou C. et al. Software and database for the analysis of mutations in the VHL gene Nucleic Acids Res 1998; 26: 256 - 8.

97. Hes F.J., van der Luijt R.B., Janssen A.L. et al. Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, southern blot analysis and multiplex ligation-dependent probe amplification Clin Genet 2007; 72: 122 - 9.

98. Van Poppel H., da Pozzo l., Albrecht W. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011; 59(4): 543 - 52. DOI: 10.1016/j.eururo.2010.12.013.

99. Kunath F., Schmidt S., Krabbe L.M. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane Database Syst Rev 2017; 5: CD012045. DOI: 10.1002/14651858.CD012045.pub2.

100. Forbes C.M., Rendon R.A., Finelli A. Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. Urol Oncol 2016; 34(11): 486.e17 - 486.e23. DOI: 10.1016/j.urolonc.2016.05.034.

101. Mir M.C., Derweesh I., Porpiglia F. Partial nephrectomy versus radical nephrectomy for clinical t1b and t2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol 2017; 71(4): 606 - 17. DOI: 10.1016/j.eururo.2016.08.060.

102. Yu-Li Jiang, Cheng-Xia Peng, Heng-Zi, Lu-Jie Qian. Comparison of the long-term follow-up and perioperative outcomes of partial nephrectomy and radical nephrectomy for 4 cm to 7 cm renal cell carcinoma: a systematic review and meta-analysis. BMC Urology 2019; 19(48). Доступно по: https: //bmcurol.biomedcentral.com/articles/10.1186/s12894-019-0480-6.

103. Gill I.S., Kavoussi L.R., Lane B.R. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007; 178: 41 - 6.

104. Bhosale P.R., Wei W., Ernst R.D. et al. Intraoperative sonography during open partial nephrectomy for renal cell cancer: does it alter surgical management? AJR Am J Roentgenol. 2014; 203(4): 822 - 827.

105. Polascik T.J., Menq M.V., Epstein J.L. et al. Intraoperative sonography for the evaluation and management of renal tumors: experience with 100 patients. J Urol. 1995; 154(5): 1676 - 80.

106. Polascik T.J., Pound C.R., Menq M.V. et al. Partial nephrectomy: technique complications and pathological findings. J Urol. 1995; 154(4): 1312 - 8.

107. Abreu A.L., Finelli A., Gill I.S. Management of localized renal cell carcinoma. Comprehensive textbook of genitourinary oncology. N.J. Vogelzang 3rd edn. LWW, 2006. P. 725 - 65.

108. Lane B.R., Tiong H.Y., Campbell S.C. Management of the adrenal gland during partial nephrectomy. J Urol 2009; 181: 2430 - 6.

109. Weight C.G., Kim S.P., Lohse C.M. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland. Eur Urol 2011; 60: 458 - 64.

110. Blom J.H.M., van Poppel H., J.M. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009; 55: 28 - 34.

111. Gratzke C., Seitz M., Bayrle F. Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma. BJU Int 2009; 104: 470 - 5.

112. Hemal A.K., Kumar A., Kumar R. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol 2007; 177: 862 - 6.

113. Gu L., Li H., Wang Z. et al. A systematic review and meta-analysis of clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with tumor thrombus treated by radical nephrectomy with thrombectomy. Cancer Treat Rev 2018; 69: 112 - 20. DOI: 10.1016/j.ctrv.2018.06.014.

114. Wagner B., Patard J. - J., A. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol 2009; 55: 452 - 60.

115. Abel E.J., Thompson R.H., Margulis V. Perioperative outcomes following surgical resection of renal cell carcinoma with inferior vena cava thrombus extending above the hepatic veins: a contemporary multicenter experience. Eur Urol 2014; 66: 584 - 92.

116. Shuch B., Crispen P.L., Leibovich B.C. et al. Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality? BJU Int 2011; 107(5): 724 - 8. DOI: 10.1111/j.1464-410X.2010.09488.x.

117. Massari F., Di Nunno V., Gatto L. et al. Should CARMENA really change our attitude towards cytoreductive nephrectomy in metastatic renal cell carcinoma? A systematic review and meta-analysis evaluating cytoreductive nephrectomy in the era of targeted therapy. Target Oncol 2018; 13(6): 705 - 14. Doi: 10.1007/s11523-018-0601-2.

118. H.A., Zapata-Copete J.A., Castillo-Cobaleda D.F. Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis 2018; 59(1): 2 - 9. DOI: 10.4111/icu.2018.59.1.2.

119. Petrelli F., Coinu A., Vavassori I. et al. Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis. Clin Genitourin Cancer 2016; 14(6): 465 - 72. DOI: 10.1016/j.clgc.2016.04.001.

120. Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655 - 9.

121. Mickisch G.H., Garin A., van Poppel H. et al. European Organisation for Research and Treatment of Cancer (EORTC) genitourinary group radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966 - 70.

122. Hanna N., Sun M., Meyer C.P. et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. J Clin Oncol 2016; 34(27): 3267 - 75.

123. Heng D.Y., Wells J.C., Rini B. et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium Eur Urol 2014; 66(4): 704 - 10.

124. A., Ravaud A., Thezenas S. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018; 379: 417 - 27.

125. Bex A., Mulders P., Jewett M. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME Randomized Clinical Trial. JAMA Oncol 2019; 5(2): 164 - 70. DOI: 10.1001/jamaoncol.2018.5543.

126. Волкова М.И., Взгляд онкоуролога на исследование CARMENA. Злокачественные опухоли 2018; 8(4): 26 - 9.

127. Barbastefano J., Garcia J.A., Elson P. et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor targeted therapy BJU International 2010; 106(9): 1266 - 9.

128. Матвеев В.Б., Волкова М.И. Рак почки. РМЖ 2007; 14: 1094.

129. Alt A.L., Boorjian S.A., Lohse C.M. et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011; 117: 2873.

130. Petralia G., Roscigno M., Zigeuner R. et al. 450 complete metastasectomy is an independent predictor of cancer-specific survival in patients with clinically metastatic renal cell carcinoma. Eur Urol 2010; 9(2): 162.

131. Dabestani S., Marconi L., Hofmann F. et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 2014; 15(12): e549 - 61.

132. Ouzaid I., Capitanio U., Staehler M. Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. Eur Urol Oncol. 2019; 2(2): 141 - 149.

133. Tomberg S.V., Visapaa H., Kilpelainen T.P. et al. Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era. Scand J Urol. 2018: 52(5 - 6): 419 - 426.

134. Guo Q., Zhang C., Guo X. et al. Incidence of bone metastasis and factors contributing to its development and prognosis in newly diagnosed renal cell carcinoma: a population-based study. Cancer Manag Res. 2018; 10: 2935 - 2944. DOI: 10.2147/CMAR.S170083.

135. Stenman M., Sinclair G., Paavola P. et al. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005 - 2014. Radiother Oncol. 2018; 127(3): 501 - 506.

136. Pierorazio P.M., Johnson M.H., Patel H.D. et al. Management of renal masses and localized renal cancer: systematic review and meta-analysis. J Urol 2016; 196(4): 989 - 99. DOI: 10.1016/j.juro.2016.04.081.

137. Guo R.Q., Li X.G. Comparison of survival benefits of nephron-sparing intervention or active surveillance for patients with localized renal masses: a systematic review and meta-analysis. BMC Urol 2019; 19(1): 74. DOI: 10.1186/s12894-019-0503-3.

138. Sun M., Bianchi M., Trinh Q.D. et al. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged >= 75 years with multiple comorbidities. BJU Int 2013; 111: 67 - 73.

139. Zini L., Perrotte P., Jeldres C. et al. A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. BJU Int 2009; 103: 899.

140. Sun M., Becker A., Tian Z. et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing-risks of death tradeoffs between surgery and acive surveillance. J Urol 2013; 189: e672.

141. Huang W.C., Pinheiro L.C., Russo P. et al. Surveillance for the management of small renal masses: outcomes in a population-based cohort. J Urol 2013. P. e483.

142. Hyams E.S., Pierorazio P.M., Mullins J.K. et al. Partial nephrectomy vs non-surgical management for small renal massess: a population-based comparison of disease-specific and overall survival. J Urol 2012; 187: E678.

143. Pierorazio P., McKiernan J., Allaf M. et al. Quality of life on active surveillance for small masses versus immediate intervention: interim analysis of the DISSRM (delayed intervention and surveillance for small renal masses) registry. J Urol 2013; 189: e259.

144. Herrera-Caceres J.O., Jewett M.A.S. Roles for active surveillance in renal cancer. Curr Opin Urol. 2018; 28(4): 375 - 382. doi: 10.1097/mou.0000000000000506

145. Rivero J.R., de La Cerda J. 3rd et al. Partial nephrectomy versus thermal ablation for clinical stage t1 renal masses: systematic review and meta-analysis of more than 3,900 patients. J Vasc Interv Radiol 2018; 29(1): 18 - 29.

146. Pan X.W., Cui X.M., Huang H. et al. Radiofrequency ablation versus partial nephrectomy for treatment of renal masses: A systematic review and meta-analysis. Kaohsiung J Med Sci 2015; 31: 649 - 58.

147. Patel N., Cranston D., Akhtar M.Z. et al. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int 2012; 110(9): 1270.

148. Takaki H., Yamakado K., Soga N. et al. Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma. Jpn J Radiol 2010; 28: 460 - 8.

149. Arnoux V., Descotes J.L., Sengel C. et al. Perioperative outcomes and mid-term results of radiofrequency ablation and partial nephrectomy in indications of renal tumor treatment and imperative nephron-sparing procedure. Prog Urol 2013; 23(2): 99 - 104.

150. Liu N., Huang D., Cheng X. et al. Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: Comparison of long-term oncologic outcomes in both clear cell and non-clear cell of the most common subtype. Urol Oncol 2017; 35: 530.e6

151. Lian H., Guo H., Zhang G. et al. Single-center comparison of complications in laparoscopic and percutaneous radiofrequency ablation with ultrasound guidance for renal tumors. Urology 2012; 80(1): 119 - 24.

152. Young, E.E., Castle S.M., Gorbatiy V. et al. Comparison of safety, renal function outcomes and efficacy of laparoscopic and percutaneous radio frequency ablation of renal masses. J Urol 2012; 187(4): 1177 - 82.

153. Trudeau, V., Larcher A., Boehm K. et al. Comparison of postoperative complications and mortality between laparoscopic and percutaneous local tumor ablation for t1a renal cell carcinoma: a population-based study. Urology 2016; 89: 63 - 7.

154. Kim S.D., Yoon S.G., Sung G.T. et al. Radiofrequency ablation of renal tumors: four-year follow-up results in 47 patients. Korean J Radiol 2012; 13(5): 625 - 33.

155. Atwell T.D., Schmit G.D., Boorjian S.A. et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol 2013; 200: 461 - 6.

156. Samarasekera D., Khalifeh A., Autorino R., Kaouk J. Percutaneous radiofrequency ablation versus percutaneous cryoablation: long-term outcomes following ablation for renal cell carcinoma. J Urol 2013; 189: e737 - 8.

157. Ortiz-Alvarado O., Anderson J.K. The role of radiologic imaging and biopsy in renal tumor ablation. World J Urol. 2010; 28(5): 551 - 557.

158. O'Neal D., Cohen T., Peterson C. Contrast-Enhanced Ultrasound-Guided Radiofrequency Ablation of Renal Tumors. J Kidney Cancer VHL. 2018; 5(1): 7 - 14.

159. Fokas E., Henzel M., Hamm K. et al. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery? Analysis of 88 patients. Strahlenther Onkol 2010; 186(4): 210 - 7.

160. Ikushima H., Tokuuye K., Sumi M. et al. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2000; 48(5): 1389 - 93.

161. Zelefsky M.J., Greco C., Motzer R. et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2012; 82(5): 1744 - 8.

162. Hunter G.K., Balagamwala E.H., Koyfman S.A. et al. The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. Pract Radiat Oncol 2012; 2(4): e95 - 100.

163. Sarna G., Figlin R., de Kernion J. Interferon in renal cell carcinoma. The UCLA experience. Cancer 1987; 59: 610 - 2.

164. Cai W., Huang J., Yuan Y. et al. Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus. Urol Int 2018; 101(4): 391 - 9. DOI: 10.1159/000492723.

165. Rini B.I., Plimack E.R., Takagi T. et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol 2015; 194: 297 - 303.

166. Karam J.A., Devine C.E., Urbauer D.L. et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol 2014; 66(5): 874 - 80.

167. Riaz I.B., Faridi W., Husnain M. et al. Adjuvant therapy in high-risk renal cell cancer: a systematic review and meta-analysis. Mayo Clin Proc 2019; 94(8): 1524 - 34. DOI: 10.1016/j.mayocp.2019.01.045.

168. Karakiewicz P., Zaffuto E., Kapoor A. et al. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Can Urol Assoc J 2018; 12(6): 173 - 80. DOI: 10.5489/cuaj.5187.

169. Messing E.M., Manola J., Wilding G. et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21: 1214 - 22.

170. Hinotsu S., Kawai K., Ozono S. et al. Randomized controlled study of natural interferon alpha as adjuvant treatment for stage II or III renal cell carcinoma. Int J Clin Oncol 2013; 18: 68 - 74.

171. Ravaud A., Motzer R.J., Pandha H.S. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 2016; 375: 2246 - 54.

172. Haas N.B., Manola J., Uzzo R.G. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016; 387: 2008 - 16.

173. Motzer R.J., Haas N.B., Donskov F. et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 2017; 35: 3916 - 23.

174. Gross-Goupil M., Kwon T.G., Eto M. et al. Axitinib versus placebo as an adjuvant treatment for renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 2018; 29: 2371 - 8.

175. Rini B.I., Halabi S., Rosenberg J.E. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137 - 43.

176. Escudier B., Pluzanska A., Koralewski P. et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370(9605): 2103 - 11.

177. Figlin R.A., Hutson T.E., Tomczac P. et al. Overall survival with sunitinib versus interferon alfa as first-line treatment in metastatic renal-cell carcinoma. ASCO Annual Meeting Proceedings 2008. J Clin Oncol 2008; 26(Suppl.): 5024.

178. Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061 - 8.

179. Motzer R.J., Hutson T.E., Cella D. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369(8): 722 - 31.

180. Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271 - 81.

181. Choueiri T.K., Halabi S., Sanford B.L. et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 2017; 35: 591 - 7.

182. Motzer R.L., Tannir N.M., McDermott D.F. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378(14): 1277 - 90.

183. Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1116 - 27

184. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125 - 34.

185. Motzer R.J., Rini B.I., Michaelson M. et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncology 2005; 23: abstr. 4508. 6-6-2005.

186. Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449 - 56.

187. Rini B.I., Escudier B.J., Michaelson M.D. et al. Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy. J Clin Oncol 2012; 30 (Suppl. 5): 354.

188. Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016; 17: 917 - 27.

189. Hutson T.E., Larkin J.M., Gold A. et al. A phase Ib clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). J Clin Oncol 2013; 31 (Suppl. 6): 358.

190. Motzer R.J., Escudier B., McDermott D.F. et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373: 1803 - 13.

191. Gore M.E., Szczylik C., Porta C. et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757.

192. P, Calvo E., I. Non-clear cell advanced kidney cancer: is there a gold standard? Anticancer Drugs 2011; 22 (Suppl. 1): 9 - 14.

193. Koh Y., Lim H.Y., Ahn J.H. et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol 2013; 24(4): 1026 - 31.

194. Escudier B., Molinie V., Bracarda S. et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer 2016; 69: 226 - 35.

195. Rini B., Plimack E.R., Stus V. et al. KEYNOTE-426 Investigators. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380(12): 1116 - 27. DOI: 10.1056/NEJMoa1816714.

196. Deng H., Huang Y., Hong Z. et al. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis. BMC Cancer 2019; 19(1): 489. DOI: 10.1186/s12885-019-5704-3.

197. Iacovelli R., Ciccarese C., Bria E. et al. Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. Cancer Treat Rev 2018; 70: 112 - 7. DOI: 10.1016/j.ctrv.2018.08.007.

198. Rousseau B., Kempf E., Desamericq G. et al. First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis. Crit Rev Oncol Hematol 2016; 107: 44 - 53. DOI: 10.1016/j.critrevonc.2016.08.012.

199. Wallis C.J.D., Klaassen Z., Bhindi B. et al. First-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol 2018; 74(3): 309 - 21. DOI: 10.1016/j.eururo.2018.03.036.

200. Hahn A.W., Klaassen Z., Agarwal N. et al. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2019; 2(6): 708 - 715. DOI: 10.1016/j.euo.2019.09.002.

201. Mills E.J., Rachlis B., O"Regan C. et al. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 2009; 9: 34. DOI: 10.1186/1471-2407-9-34.

202. Edwards S.J., Wakefield V., Cain P. et al. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 2018; 22(6): 1 - 278. DOI: 10.3310/hta22060.

203. Amzal B., Fu S., Meng J. et al. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. PLoS One 2017; 12(9): e0184423. DOI: 10.1371/journal.pone.0184423.

204. Larkin J., Paine A., Tumur I. et al. Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. Expert Opin Pharmacother 2013; 14(1): 27 - 39. DOI: 10.1517/14656566.2013.758713.

205. El Rassy E., Aoun F., Sleilaty G. et al. Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety. Future Oncol. 2017; 13(29): 2709 - 2717. DOI: 10.2217/fon-2017-0268.

206. Wen T., Xiao H., Luo C. et al. Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis. Oncotarget. 2017; 8(12): 20441 - 20451. DOI: 10.18632/oncotarget.14671.

207. Kok V.C., Kuo J.T. Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment. BMC Urol. 2016; 16(1): 34. DOI: 10.1186/s12894-016-0156-4.

208. Bellmunt J., Esteban E., Muro X.G.D. et al. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. Eur Urol Oncol. 2019; S2588 - 9311(19): 30117 - 8. DOI: 10.1016/j.euo.2019.07.014

209. Seymour L1, Bogaerts J2, Perrone A iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar; 18(3): e143 - e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2.

210. Yasar H.A., Bir Yucel K., Arslan C. et al. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer. J Oncol Pharm Pract. 2019 Oct 25: 1078155219883004. DOI: 10.1177/1078155219883004. [Epub ahead of print]

211. Miyake H., Tei H., Fujisawa M. Geriatric Nutrition Risk Index is an Important Predictor of Cancer-Specific Survival, but not Recurrence-Free Survival, in Patients Undergoing Surgical Resection for Non-Metastatic Renal Cell Carcinoma. Curr Urol. 2017; 10(1): 26 - 31. DOI: 10.1159/000447147.

212. Tahbaz R., Schmid M., Merseburger A.S. Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Curr Opin Urol. 2018; 28(1): 62 - 79. DOI: 10.1097/MOU.0000000000000454.

213. Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatment related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2103; 92(8): 715 - 27.

214. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological prehabilitation before cancer surgery: A Systematic Review. Ann Surg Oncol 2015; 22(13): 4117 - 23. DOI: 10.1245/s10434-015-4550-z.

215. Swarm R., Abernethy A.P., Anghelescu D.L. et al. Adult Cancer Pain. J Natl Compr Canc Netw 2010; 8(9): 1046 - 86.

216. Azhar R.A., Bochner B., Catto J. et al. Enhanced recovery after urological surgery: a contemporary systematic review of outcomes, key elements, and research needs. Eur Urol 2016; 70(1): 176 - 87.

217. Recart A., Duchene D., White P.F. et al. Efficacy and safety of fast-track recovery strategy for patients undergoing laparoscopic nephrectomy. J Endourol 2005; 19(10): 1165 - 9.

218. Shin K.Y., Guo Y., Konzen B. et al. Inpatient cancer rehabilitation: the experience of a national comprehensive cancer center. Am J Phys Med Rehabil 2011; 90(5): 63 - 8.

219. Bourke L., Homer K.E., Thaha M.A. et al. Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review. Br J Cancer 2014; 110: 831 - 41.

220. Hunter E.G., Baltisberger J. Functional outcomes by age for inpatient cancer rehabilitation: a retrospective chart review. J Appl Gerontol 2013; 32(4): 443 - 56.

221. Segal R., Zwaal C., Green E. et al. Exercise for people with cancer guideline development G: Exercise for people with cancer: a systematic review. Curr Oncol 2017; 24(4): e290 - e315.

222. Hu C., Zhang H., Wu W. et al. Acupuncture for pain management in cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2016; 2016: 1720239.

223. Mehling W.E., Jacobs B., Acree M. et al. Symptom management with massage and acupuncture in postoperative cancer patients: a randomized controlled trial. J Pain Symptom Manage 2007; 33(3): 258 - 66.

224. Lee S.H., Kim J.Y., Yeo S. et al. Meta-analysis of massage therapy on cancer pain. Integr Cancer Ther. 2015; 14(4): 297 - 304.

225. Boyd C., Crawford C., Paat C.F. et al. Evidence for massage therapy working G: the impact of massage therapy on function in pain populations-A systematic review and meta-analysis of randomized controlled trials: Part II, Cancer Pain Populations. Pain Med 2016, 17(8): 1553 - 68.

226. Kessels E., Husson O., van der Feltz-Cornelis C.M. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat 2018; 14: 479 - 94.

227. Rief H., Omlor G., Akbar M. et al. Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial. BMC Cancer 2014; 14: 67.

228. Bensadoun R.J., Nair R.G. Low-Level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg 2015; 33(10): 487 - 91.

229. Beisland C., G., L.A. et al. A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. World J Urol 2016; 34(8): 1087 - 99.

230. Eggener S.E., Yossepowitch O., Pettus J.A. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006; 24(19): 3101 - 6.

231. International Agency for Research on cancer (IARC). WHO IARC monographs. 2004. 83. Available on: https: //monographs.iarc.fr/wp-content/uploads/2018/06/mono83.pdf.

232. Doehn C., V., Steiner T. et al. The diagnosis, treatment, and follow-up of renal cell carcinoma. Dtsch Arztebl Int. 2016; 113(35 - 36): 590 - 6.